Unusual Biotech Movers (ASTM, BTRX, BCRX, CELG, NSTK, TRMS)
If you are a stem cell watcher, you may want to watch Aastrom Biosciences Inc. (NASDAQ: ASTM) as it reports earnings on Monday. Shares are down 3% at $0.40 today. With a $53 million market cap, this isn't the most influential stock tied to stem cells.
Barrier Therapeutics Inc. (NASDAQ: BTRX) saw some highly unusual movement with a 15% rise to $2.31 (52-week trading range $1.63 to $7.60).
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) saw a continues drop of almost 7% to $2.73 today, and that is after a similar drop yesterday after the company's earnings report.
Celgene Corporation (NASDAQ: CELG) saw a 1% drop to $61.80. We saw a duel in analyst calls today, and generally speaking downgrades take away more 'ooomph' than upgrades can add on the same day, particularly when the downgrade is from a bulge bracket firm and the upgrade is by a boutique. Pacific Growth Equities raised its rating to Buy, but Credit Suisse lowered its rating to Neutral from outperform.
Nastech Pharmaceutical Company, Inc. (NASDAQ: NSTK) saw a drop of more than 8% to $1.19 after its earnings report yesterday. 52-week trading had been $1.25 to $17.05. Count that as a 52-week low.
Shares of Trimeras Inc. (NASDAQ: TRMS) are down 9% at $6.35 today after the company has unveiled its plans to return most of its cash to shareholders now that it is down to a whopping 10 employees. At $50, 5-years ago, this stock has gone from potential boom to bust. Why does the term biotech zombie ring a bell here????
Rachel Lopez
May 9, 2008
Barrier Therapeutics Inc. (NASDAQ: BTRX) saw some highly unusual movement with a 15% rise to $2.31 (52-week trading range $1.63 to $7.60).
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) saw a continues drop of almost 7% to $2.73 today, and that is after a similar drop yesterday after the company's earnings report.
Celgene Corporation (NASDAQ: CELG) saw a 1% drop to $61.80. We saw a duel in analyst calls today, and generally speaking downgrades take away more 'ooomph' than upgrades can add on the same day, particularly when the downgrade is from a bulge bracket firm and the upgrade is by a boutique. Pacific Growth Equities raised its rating to Buy, but Credit Suisse lowered its rating to Neutral from outperform.
Nastech Pharmaceutical Company, Inc. (NASDAQ: NSTK) saw a drop of more than 8% to $1.19 after its earnings report yesterday. 52-week trading had been $1.25 to $17.05. Count that as a 52-week low.
Shares of Trimeras Inc. (NASDAQ: TRMS) are down 9% at $6.35 today after the company has unveiled its plans to return most of its cash to shareholders now that it is down to a whopping 10 employees. At $50, 5-years ago, this stock has gone from potential boom to bust. Why does the term biotech zombie ring a bell here????
Rachel Lopez
May 9, 2008
posted by Nico at
12:44 PM
1 Comments:
If you do notice a change, and it continues for an extended period of time despite dietary changes, you should see your GP to find out if there is anything they can suggest to help with your situation. Hot beverages – whilst we all tend to enjoy a tea or coffee as a refreshment or pick-me-up, they do have a diuretic effect. Diuretics increase the production of urine, meaning we have to visit the loo more than usual. Bear this in mind when drinking coffee to help encourage a movement.
https://www.offerplox.com/cbd-products/proper-cbd-gummies/
https://www.supplementz.org/gold-coast-keto/
https://www.supplementz.org/vibez-keto-gummies/
https://www.offerplox.com/skin-care/amarose-skin/
https://www.offerplox.com/weight-loss/figur-kapseln/
https://www.offerplox.com/weight-loss/gold-coast-keto/
https://www.offerplox.com/weight-loss/vibez-keto-gummies/
Post a Comment
Subscribe to Post Comments [Atom]
<< Home